HotSpot Therapeutics has dosed the first patient in a Phase I/II clinical study of HST-1011 for treatment of patients with advanced solid tumours.

The study has been designed to evaluate HST-1011 alone and in combination with Regeneron Pharmaceuticals’ anti-PD-1 therapy, Libtayo (cemiplimab).

As part of the trial, HotSpot Therapeutics signed a clinical supply agreement with Regeneron for Libtayo, a fully human monoclonal antibody.

HotSpot chief development officer Tim Reilly said: “Dosing of the first patient with HST-1011 is an important milestone for HotSpot signifying our evolution into a clinical-stage company with the first-in-human dosing of a product candidate derived from our proprietary Smart Allostery drug discovery platform.

“Importantly, we believe that HST-1011, as a highly potent and selective inhibitor of the long sought after target CBL-B, may represent an important new immunotherapy treatment option for cancer patients.”

Patients with advanced solid tumours that are relapsed on or are refractory to anti-PD(L)-1 or standard of care therapies, are enrolled for the combination therapy study.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

HotSpot Phase I/II clinical study principal investigator and University of Pittsburgh Medical Center’s Hillman Cancer Center, Immunotherapy and Drug Development Center director Jason Luke said: “Despite tremendous progress in the field of immuno-oncology (I-O), significant unmet need persists for patients with advanced solid tumours, as many cancers are found to be unresponsive to or lack durable responses following treatment with currently available therapies.

“We believe CBL-B’s role as a master regulator of immune cell activation presents a differentiated therapeutic opportunity.”